Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status
| Autor: | John R. McLaughlin, Taymaa May, Barry P. Rosen, Joanne Kotsopoulos, Ping Sun, Isabel Fan, Harvey A. Risch, Steven A. Narod, Joel Moody |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
0301 basic medicine Oncology medicine.medical_specialty endocrine system diseases Genes BRCA2 Genes BRCA1 Disease Carcinoma Ovarian Epithelial Cohort Studies Young Adult 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans Genetic Predisposition to Disease Neoplasms Glandular and Epithelial Young adult Survival rate Aged Neoplasm Staging Ontario Ovarian Neoplasms Gynecology business.industry BRCA mutation Obstetrics and Gynecology Middle Aged medicine.disease female genital diseases and pregnancy complications Cancer registry Survival Rate Serous fluid 030104 developmental biology 030220 oncology & carcinogenesis Mutation Mutation (genetic algorithm) Female business Ovarian cancer |
| Zdroj: | Gynecologic Oncology. 140:42-47 |
| ISSN: | 0090-8258 |
| DOI: | 10.1016/j.ygyno.2015.11.009 |
| Popis: | Objectives After a diagnosis of ovarian cancer, positive BRCA mutation status confers a transient mortality benefit that diminishes with time. The majority of women who survive for 10–12years are effectively cured of their disease. Thus, it is important to estimate the probability of long-term survival by BRCA mutation status and treatment-related factors. Methods We included unselected epithelial ovarian cancers diagnosed in Ontario, Canada from 1995 to 1999 and from 2002 to 2004. Clinical information was obtained from medical records. Survival status was determined by linkage to the Ontario Cancer Registry. We estimated the annual mortality for these patients. We compared women who did and did not survive 10years for a range of factors including BRCA mutation status and extent of residual disease post-surgery. Results Of the 1421 patients, 109 (7.7%) had BRCA1 mutations and 68 (4.8%) had BRCA2 mutations. A status of no residual disease was achieved by 39% of non-carriers and 19% of mutation carriers ( P BRCA1 mutation carriers and 69% of BRCA2 mutation carriers had died from ovarian cancer. Among women with stage III/IV serous cancers and no residual disease, the 10-year actuarial survival was 42% for non-carriers and 29% for mutation carriers ( P =0.40). Conclusion The initial survival advantage among women with BRCA mutations may reflect a higher initial sensitivity of BRCA carriers to chemotherapy, but this response does not predict long-term survival. The strongest predictor of long-term survival is status of no residual disease at resection. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect